Product Information
GENTAMICIN 80 MG/2 ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $1.3026 per ML under NDC 63323001094. Its NADAC has been published 432 times since May 21, 2014.
FDA first approved this application on Aug 4, 1983. Its Orange Book therapeutic-equivalence code is AP.
Strength
40 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323001094
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
GENTAMICIN SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA062366FDA Approved
8/4/1983
TE Code
AP
On Market Since
8/10/2000
Pharmacological Classes
Price Statistics
The NADAC for GENTAMICIN 80 MG/2 ML VIAL has been published 432 times since May 21, 2014, and over the history we have for it it has risen 22.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3026 per ML |
|---|---|
| All-time high | $1.8675 (Nov 13, 2024) |
| All-time low | $0.5032 (Aug 17, 2016) |
| 52-week high | $1.6728 |
| 52-week low | $1.3026 |
| Median price | $0.9108 |
| Average price | $1.0428 |
| Largest weekly change | +121.9% (Feb 19, 2020) |
| Weeks tracked | 432 |
| Tracking since | May 21, 2014 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 28% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
GENTAMICIN SULFATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoglycoside Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GENTAMICIN 80 MG/2 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for GENTAMICIN 80 MG/2 ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $1.3026 per ML (NDC 63323001094), effective Sep 30, 2026.
How has the price of GENTAMICIN 80 MG/2 ML VIAL changed over time?
Over the history we have for it, the NADAC for GENTAMICIN 80 MG/2 ML VIAL has risen 22.1%. It has been tracked across 432 weekly CMS publications since May 21, 2014.
What are the highest and lowest recorded NADAC prices for GENTAMICIN 80 MG/2 ML VIAL?
Since May 21, 2014, the NADAC for GENTAMICIN 80 MG/2 ML VIAL has ranged from a low of $0.5032 (Aug 17, 2016) to a high of $1.8675 (Nov 13, 2024), with a median of $0.9108 per ML.
Are there cheaper alternatives to GENTAMICIN 80 MG/2 ML VIAL?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GENTAMICIN 40 MG/ML VIAL, is $0.9335 per ML — about 28% below GENTAMICIN 80 MG/2 ML VIAL.
Who manufactures GENTAMICIN 80 MG/2 ML VIAL?
GENTAMICIN 80 MG/2 ML VIAL (NDC 63323001094) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.